Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC-300
- Development stage
- Unknown
- Lead developer
- Viatris
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
01
Overview
OC-300 is an investigational **bacteriophage therapy** originally attributed to Oyster Point Pharma. Publicly accessible drug intelligence sources identify it as a preclinical or very early clinical-stage program, but they do not provide a verified molecular composition, defined phage cocktail content, specific biological target, route of administration, or clear lead indication. Based on the available evidence, the safest characterization is that OC-300 is a named phage-based anti-infective development candidate with insufficient public disclosure to support a more specific mechanism-of-action annotation.
- Other names
- bacteriophage therapy
Beyond the preview
Go deeper on OC-300.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC-300.